Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I disagree with this false price ceiling. If I were short I'd be setting these sort of fake price ceilings.
SNO 2022 could be a bust for investors like NYAS and it will be if NWBO does not learn anything about effective public and investor communications and fixed lifelong bad habits in a handful of months is unlikely.
The last few months have proven to put charge in that spreading awareness among scientists has little impact for shareholders.
Furthermore SNO 2022 could well be another placeholder as we all learned the hard way back in 2020.
If something happens, great but slapping a bunch of logos up there does not counterbalance the historical cycle of hype and crushing disappointment here.
I'd agree with this nonsense narrative if I were a short. I'm long so I disagree.
have a great one HL!
Chris Brown and his hedge fund which is shorting nwbo would agree with this bullshit narrative!
LOL at this bullshit short narrative. I couldn't read past the first sentence.
have a good one Mav
complete nonsense. management needs funds to keep the lights on. they are using the minimum amount of c shares to do so.
Yeah I think the 70 per share comments are a pipe dream. We’re luck if we get to 2.00. Dilution is a bitch that bites you in the ass.
Now if you’re one the end of the dilution, like getting millions of shares, a buck increase isn’t bad.
we are in a quiet period. the pr push hasn't started.
Exactly, we’ve all seen this before and it involves months more of dragging out and another disappointment that many will not admit is even a disappointment.
Thanks TDD! A busy 2022 and more to come!
Thanks biosectinvestor. I have read through your response briefly and get the gist of what you are saying, but I need to read it a bit more for understanding and may have some follow-up questions for you.
The aspect of the company being shorted due to the terms of the contract reminds me of companies I've followed in the past that get themselves into convertible note financing with conversion prices determined by the average price "x" days from key dates defined in the note. The stock price mysteriously drops around these key dates and the stock gets diluted to the point of no return. Often these companies never do return. NWBO has been able to hang in there and it seems we may get to see them cross the finish line of regulatory approvals and ultimately becoming standard of care for GBM.
I agree with you. It’s done to benefit a narrow group of investors while poor retail gets sucked!
The PRs and statements at conferences in the last 10 odd years give us enough evidence that they have been BSing us, no?
From official statements in mid 2010s saying data lock coming soon to presentation by LP to scientific community in summer of 2020 at a virtual meeting that we will be unblinding in the coming weeks to LG’s appearance on big booze show in summer 2020 saying UK approval imminent….what additional proof do you need?
They have not been able to tackle the shorts for over 10 years now. They know what was coming and yet botched May 10. Given their repeated failures, no guarantee it won’t happen again. You could argue this is done to benefit a narrow set of investors to pump and dump, suck more retail.
Why are they hiding behind the quiet period for 2 years post data lock when they ought to be going out there convincing the street as to the real value of our platform, particularly with the stellar ph 3 data. Something smells fishy? Give me example of one successful biotech company that has taken this strategy? Importantly, why would you dilute the company at such low share price when you are in possession of such great data for months now and approvals that are imminent? The investors ought to be dancing on our tunes to invest in us!
You have to ask management why they wish to sell C shares at this level and why they value the stock here. It seems they are depressing the price.
I agree but some this stuff that’s been recently presented seems like the company is getting close.
My only concern is that if this truly is a miracle cure, where are the big boys and girls. How is this company sitting at 70 cents. I would think that companies like Merck would be all over this. I’m sure they have people / departments that look for promising treatments. The lack of run up in the PPS is perplexing.
Stick around for ten years and you can get all the promises made and broken.
“Use that opportunity to invest in a company with a dynamic and driven management team that takes accountability for their actions and do not play victim card or blame game. “
I am just waiting for new management. I had a discussion with Senti about when the Cs were shopped. To be honest these guys are probably shopping shares 24/7 365. To blame shorts after the reveal seems to stretch the envelope. What short would take a position without knowing the results that were pretty good? Especially for rGBM. What if the results were even better or they promoted the results properly. But you would look for a downturn if you had knowledge they were willing to sell shares at this current price. These leaders are not the financial wizards they are made out to be. They have hurt most shareholders and languished assets. That is just my take. Anyone disagrees it is an open forum.
Thank you for posting these solid facts.
Those that support the company seem to provide facts. Any facts to support your post. Thanks
Nice Danish Dude. Thanks:)
I have compiled a "what has happened in 2022" guide or in other terms "Let's pump it" for those who haven't heard of the phenomenons of reason, rationality, logic, that makes it possible to put forth information and thesis that are qualified with regards to being either uncompromising facts, or very probable.
Let's take a stroll down the 2022 memory lane and sum up, why the NWBO stock currently is the best stock investment since Gamestop around new years eve 2020, at this ridicolous price level.
Facts
January 9th.
The use of the external control arms trial design gets thumbs up by FDA, as the article "External Control Arms in Oncology: Current Use and Future Directions", gets printed in Annals of Oncology. 12 co-authors, among these dr. Richard Pazdur, ALL affiliated with U.S. Food and Drug Administration, also known as FDA.
January 11th.
AdventBio announces their new Cryostore and Freezer facility at Sawston.
January 23rd.
It is found out, that dr. Roger Stupp, the man behind The Stupp protocol, which became standard of care for the treatment of glioblastoma (GBM) since its publication in 2005, became an advisor to NWBO BEFORE September 26th. 2020.
January 27th, February 17 and 26th.
3 articles in british newspapers specifying the NWBO and AdventBio connection, with the later dedicated to do NWBO's bidding as a CDMO in terms of manufactoring and production.
When reading, one is not in doubt of the "mother-child" setup and what is AdventBio's main purpose.
"Northwest Biotherapeutics has secured MHRA certification for its cancer vaccine trials in the Sawston Business Park, sparking delight for site developer Advent BioServices. Advent, which is based on the Park, has completed the laboratory facilities to UK regulatory standards on behalf of Northwest Biotherapeutics, which is headquartered in Bethesda, Maryland. NW Bio’s Sawston R&D team is working on a cancer vaccine for glioblastoma multiforme, the most aggressive type of brain cancer."
"That’s actually another project, we’re working on getting collaboration with Mark Gilbert and NCI. We’re actually trying to collect all these people, because even in our immunotherapy trials, I think we have about 50 of them now, that are over 5 years going on 10 years"
“The group that got dendritic cell vaccination plus poly-ICLC had a 50% survival rate and now the majority of these patients are reaching 100 months and with not only survival but really no tumor recurrence.”
"Thank you for your email, your information and your advice. We communicate directly with Linda Powers at NWBio and most recently facilitated her contributing to a meeting with UK politicians as part of an inquiry into the pathway to a cure for brain tumour patients."
With more than 25 years of experience in strategic communications at global PR agencies and in politics, Michael has advised leading global companies, promising start-ups, respected organizations and political candidates across the full range of communications, media and reputation management activities. He leads the Corporate Communications Group at ICR and specializes in corporate positioning, executive coaching, crisis, transactions and special situations.
Michael has provided communications counsel on more than 100 IPOs, scores of M&A transactions.
"The GMP Production Scientist will be responsible for performing batch manufacturing of the company’s contract manufacturing products to support the delivery, in the first instance, of Advanced Therapeutic Medicinal Products (ATMPs) as both ”Specials” and as Investigational Medicinal Products (IMPs). The post holder will work closely with GMP Production Scientists, Quality Assurance Scientists and facilitate the efficient delivery of cellular therapy products for clinical use."
"The MHRA license approval enables the manufacturing of DCVax-L products to get under way at the Sawston facility in addition to continuing at the smaller GMP facility in London. The license also permits the import and GMP manufacture of other cell therapy products under the UK’s supply of unlicensed medicinal products (‘Specials’) regime and for clinical trials under the Investigational Medicinal Products (IMP) Programme."
A lot of talk going around regarding instability with financial institutions and hedge funds, specifically in the EU and Sweden.
Obviously there are broader implications that come with this, but I hope NWBO does not get affected in any way due to the turbulence of the financial markets:
https://m.investing.com/news/stock-market-news/blackrock-says-reducing-leverage-in-ldi-funds-2903030
The collapse in Credit Suisse's share price is of great concern. From $14.90 in Feb 2021, to $3.90 currently, markets are saying it's insolvent and probably bust. pic.twitter.com/RIBlqKLtvm
— Alasdair Macleod (@MacleodFinance) September 30, 2022
The Bank of England kickstarted QE this week due to pension funds potentially collapsing.
— Gold Telegraph ⚡ (@GoldTelegraph_) October 1, 2022
People forget that the Bank of England's bond portfolio losses are already £200 Billion.
Enjoy the show.
Deutsche Bank and Credit Suisse are tanking more right now than the financial crisis of 2009. There are so many market indicators that we are heading towards a major financial crisis. $DB $CB pic.twitter.com/AfkCX3yr9V
— James Melville 🚜 (@JamesMelville) October 1, 2022
Fascinating article Abeta! Thank you!
Will NWBO has ASM this year? Is that legal without annual ASM?
Re: None
Saturday, October 01, 2022 5:51:55 PM
Post#
518324
of 518351
Sept 30 2022 - Glioblastoma recurrence reveals novel and targetable immunoregulatory drivers
NOTE: p means Primary
We, therefore, quantified the transcriptome and proteome of 134 patient-derived pGBM and rGBM samples, including 40 matched pGBM-rGBM pairs.
GBM subtypes transition from pGBM to rGBM towards a preferentially mesenchymal state at recurrence, consistent with the increasingly invasive nature of rGBM.
We identified immune regulatory/suppressive genes as important drivers of rGBM and in particular 2-5-oligoadenylate synthase 2 (OAS2) as an essential gene in recurrent disease.
Our data identify a new class of therapeutic targets that emerge from the adaptive response of pGBM to therapy, emerging specifically in recurrent disease and may provide new therapeutic opportunities absent at pGBM diagnosis.
https://pubmed.ncbi.nlm.nih.gov/36178522/
note - the above is the abstract and I don't know how to get to the whole article
other than paying about $40 bucks
Sidebar
2',5'-oligoadenylate synthase (OAS) is a class of enzymes induced by interferons and mainly encoded by the OAS1, OAS2, and OAS3 genes, which activate the potential RNA enzymes to degrade viral mRNA, inhibit viral protein synthesis and promote apoptosis in virus-infected cells. OAS3 is associated with breast cancer prognosis. However, the expression and prognosis of OAS3 and tumour-infiltrating lymphocytes in pan-cancer remain unknown. In the present study, we have systematically investigated and confirmed the role of OAS3 in tumour immune infiltration, immune escape, tumour progression, response to treatment, and prognosis of different cancer types using various bioinformatics methods. The findings suggest that OAS3 is aberrantly expressed in almost all TCGA cancer types and subtypes and is associated with tumour staging, metastasis, and prognostic deterioration in different tumours. In addition, OAS3 expression is associated with the prognosis and chemotherapeutic outcomes of various cancers. In terms of immune-infiltrating levels, OAS3 expression is positively associated with the infiltration of immunosuppressive cells. These findings suggest that OAS3 is correlated with prognosis and immune-infiltrating levels.
https://pubmed.ncbi.nlm.nih.gov/35592250/
Calling a link to a talk by liau a “pump” seems strange to me- have a great one Bobby!
Judge, But 50 dma has not crossed 200 dma (78cents). Why you call it golden cross now? I am confused.
well stated bio
1) Nowhere in my post did I say you said they were mismanaged. Why are you even asking?
2) Where did I say, repeatedly "all this silence is normal". These kinds of attacks are not NORMAL. These kinds of campaigns only happen to very particularly targeted companies. I agreed with you that yes, they had not had any quarterly calls
This is exactly what I said to the comment to which you just replied.
"I said no, they haven’t had quarterly calls HFT3. I did not say that was typical. However, in my experience with companies like this, single product companies that have been massively shorted by hedge funds, it actually is quite typical to go silent. And in this case, given what I know now, I honestly believe it was the right strategy. The attacks on this company are so nasty and determined, I have no doubt they would have destroyed it. I don’t thing that would have served the interests of anyone but those shorting the company and I don’t believe therefore that I have missed anything or been disadvantaged by it. "
David, you are right I did not list the 200. I posted the 50 and the 100 bc they are on top of each other and we are imminent for 50 to cross the 100.
I called it the silver cross as a joke. But it’s a step in the right direction bc the 50 has to get over the 100!before it gets back over the 200. The 200 which is not listed is currently at 78
thanks for the chart and explanations judge!
I hear you ILT. Just wanted to be clear that I don't see that there is a clear strategy for companies to rebut those strategies and I don't see these posters as always just a few idiosyncratic posters but often they are part of what I would call troll farming efforts. These efforts don't just happen and then continue for years. There are economic interests behind them, I believe.
My views are based on my own experience with project finance and doing deals to make facilities and other projects happen.
Cognate actually invested in NWBO at very high share price by doing the work as a supplier for shares instead of cash. What is typical of such a deal is that the shares are paid at the current share price at that time, but such contracts typically have a most favored nation's clause that ensures that the end party gets shares worth the value of services provided. Typically the mechanism is not on a daily basis but is triggered when the company itself does a direct issuance. So secondary market trades don't trigger it typically. What happened was that shorts scour filings for clauses like these, but they take down the company shares by insinuating all sorts of negative things that have nothing to do with the clauses. The result is that they can trigger massive dilution, which then creates an avalanche in the share price, and the company basically is like a piñata for the hedge funds.
Those financings always sound great in the abstract, but no one expects that people will be so evil as to take things actually in financial statements, and then weaponize them through implication and suggestion, as if they are not there or as if they are not just basic issues or risks. Something like that happened here, they collapsed the share price, triggered years worth of expenses to come due immediately as shares from the company, and then used that to suggest something bad was happening between the two, which of course allowed them to keep at it. Shorts love to make a mess of these companies and then they might wait to take the assets out of bankruptcy and reflect them, or keep it private, or sell it all to another large player and they get the profit all the way down, get the assets basically stolen from naive shareholders and turn that into another billion or more in a sale or an IPO.
Wicked vulture traders. Quite nasty.
So in the end, the two companies needed to settle up old debts and renegotiate some. Cognate had its own factory and facilities, so it was not the same as this, and NWBO was nowhere near as far along when that relationship was struck. My sense of it was that there were not a lot of CDMO's or any players doing anything commercial in the dendritic cell space, and the players out there were more in the stem cell and other cell space. This is autologous too, which is also a different animal than what a lot of the cell manufacturing companies were doing. We can see from Car-T sector and Dendreon before, that really, it was very much by hand kind of by hand process that was not industrialized. So getting scale in the manufacturing of these kinds of treatments would be an advantage to everyone if it could be done. So Cognate was really a first attempt at that I believe and of course they were ultimately bought by Charles River, though I think they needed to sell at that point because basically all of NWBO's trial manufacturing was done already and there was nothing going on with their biggest customer, they were waiting for survival data, which as we know takes a long time, and I don't see a lot of other companies climbing into this space. Charles River had the resources to wait it out and be prepared for a whole new segment which I think, when they evaluated that opportunity, they likely looked at companies like NWBO and saw what is not obvious to your average investor.
Judge, please help me. where is 50 ? and 200?
We have chance for Oct, but probably be Nov to cross Centerline & 50 get > 200.
I, hoping we get some good news for the sake of cancer patients.
Daily Chart 10 Month View ~ Circled Monster Gap in Dec that is causing us to mess around with 68 & 75 level so much. I'll give Feedback from Top to Bottom:
1. Top Indicator is short term MACD ~ Year Long Support / Trend Line in play - also on Centerline. "Power Moves happen on Centerline"(I Patented that saying).
2. ROC with EMA..Pretty self explanatory. Great tool I created shows clear direction of stock. We had brief drop below and quickly popped back above(And Centerline). We all that Whipsaw to the good way.
3. Can see 50 about to cross 100 ~ Silver Cross this week.
4. Finding Support on Cloud, and also outlined Bull Flag / Falling Wedge we are in.
5. Bottom Indicator one of my favs...Long Term MACD 65,90,12. Can see the Blue circles I made when we have crossed and action that followed so far this year.
Bonus Tip....MACD setting of 65,90,12 also correlates with 50/200 Golden Cross. In other words, when this MACD crosses the Centerline, that will be with 50 will cross 200....They are closely tied at the hip most of the time. Can also observe we have made Higher Lows in 2022 for this Long Term MACD. We have chance for Oct, but probably be Nov to cross Centerline & 50 get > 200.
Sorry for the error.
It’s a 10 minute slot so it will be a nothing burger. If it was something massive, exciting & different then they would have given her more time and an important slot. I’d actually be happy if we don’t get taken down after SNO like NYAS.
Whoseleft - There have been a few fascinating breakthroughs by lonewolfs, who were resourceful stewart's of unconventional scientific approaches, and because their concepts were either not patentable, or patentable but not available to buy-off, or so incredible to believe, that the pharma barons chose to destroy any chances of these discoveries from seeing the light of day.
ILT
Biosect - If you reread my post, you'll understand that we aren't apart in our view of how rediculous a proposition would be to reflexively put out postings for any public company as a strategy to shut down falsehoods. I feel the same exact way about an investment community that can't draw the line in the sand from responding to such "RainMan like utterances" of the same false identical narratives, thinking that somehow a) they will stop and see the light, or b) stop period. One or two odd posters who can't find something new, but to play the same song, doesn't make for good listening or most popular. Unfortunately, it's not that I don't believe people aren't gullible, that I do know, but the preponderance of the long view on this board makes the efforts of the lone hitman a near impossibility to achieve whatever their misguided objectives are.
ILT
Thank you Captain, good to see warrants being exercised helping fund our company in these final stages before revenue starts to pour in! GLTA
The gift that keeps giving might prove to be very beneficial in humanity's fight against cancer! We know viruses are responsible for some cancers if not most, HPV for one is well documented. Hopefully we can turn viruses into a friend instead of a bloody enemy! GLTA
https://www.insider.com/mans-cancer-vanished-after-injection-with-weakened-herpes-virus-2022-9?amp
Code blue, code blue
50 CCs lidocaine stat
Charging……. Clear……
Zap!……… beep.. beep..
We have a pulse!
Sept 30 2022 - Glioblastoma recurrence reveals novel and targetable immunoregulatory drivers
NOTE: p means Primary
We, therefore, quantified the transcriptome and proteome of 134 patient-derived pGBM and rGBM samples, including 40 matched pGBM-rGBM pairs.
GBM subtypes transition from pGBM to rGBM towards a preferentially mesenchymal state at recurrence, consistent with the increasingly invasive nature of rGBM.
We identified immune regulatory/suppressive genes as important drivers of rGBM and in particular 2-5-oligoadenylate synthase 2 (OAS2) as an essential gene in recurrent disease.
Our data identify a new class of therapeutic targets that emerge from the adaptive response of pGBM to therapy, emerging specifically in recurrent disease and may provide new therapeutic opportunities absent at pGBM diagnosis.
https://pubmed.ncbi.nlm.nih.gov/36178522/
note - the above is the abstract and I don't know how to get to the whole article
other than paying about $40 bucks
Sidebar
2',5'-oligoadenylate synthase (OAS) is a class of enzymes induced by interferons and mainly encoded by the OAS1, OAS2, and OAS3 genes, which activate the potential RNA enzymes to degrade viral mRNA, inhibit viral protein synthesis and promote apoptosis in virus-infected cells. OAS3 is associated with breast cancer prognosis. However, the expression and prognosis of OAS3 and tumour-infiltrating lymphocytes in pan-cancer remain unknown. In the present study, we have systematically investigated and confirmed the role of OAS3 in tumour immune infiltration, immune escape, tumour progression, response to treatment, and prognosis of different cancer types using various bioinformatics methods. The findings suggest that OAS3 is aberrantly expressed in almost all TCGA cancer types and subtypes and is associated with tumour staging, metastasis, and prognostic deterioration in different tumours. In addition, OAS3 expression is associated with the prognosis and chemotherapeutic outcomes of various cancers. In terms of immune-infiltrating levels, OAS3 expression is positively associated with the infiltration of immunosuppressive cells. These findings suggest that OAS3 is correlated with prognosis and immune-infiltrating levels.
Thanks biosectinvestor! Between your response and hoffmann's I think understand what is going on with Advent. Was this the same arrangement with Cognate (loans with stipulations to provide access to others, etc)?
It’s a private company, but the rate they are being paid appears to be fair and reasonable and the fact is, there is nothing on the NWBO balance sheet that suggests they have capitalized Advent. What is clear is advent does not have its own facility, it is a contract manager. It pays NWBO a substantial rent, and needs approvals u believe to take on work in the factory if it would take away from plans by NWBO. It is a symbiotic relationship and the facility received regional development loans at a good rate in order to develop the facility with the promise that local scientific and commercial endeavors would have access to the facility. NWBO would not have received that loan were it not able to provide access to the facilities, but it would be a gross waste of resources for NWBO to man up to provide those ancillary manufacturing services itself.
So this is a very beneficial relationship. NWBO owns the factory, I can’t imagine another contract manufacturer willing to manufacture at a start-up company’s own factory other than an early stage CDMO with no capital sunk in facilities of its own.
In the end, basically the local regional authority has funded NWBO’s facility so long as it provides a certain, reasonable amount of access to its facilities and capacities to develop this sector in the region. I think it was a fair bargain. I don’t know of any companies that would refuse such funding generally at this stage of their development.
Followers
|
1625
|
Posters
|
|
Posts (Today)
|
79
|
Posts (Total)
|
713859
|
Created
|
02/02/05
|
Type
|
Free
|
Moderators XenaLives sentiment_stocks CaptainObvious Poor Man - Doc logic JerryCampbell |
“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
~ Winston Churchill
Stylized Dendritic Cell featured on NWBO board since 2015
- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA
Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind)
UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma - Phase 1 (NCT04201873)
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator: Mayo Clinic
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Cognate Bioservices - Owned by Charles River Labs
Website
Company Contact Info
Investor Relations:
Les Goldman (Company) (202) 841-7909 lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)
Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 (240) 497-9024
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.
Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.
Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.
They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
DCVAX Survival Stories & Testimonials
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
Presentations
UCLA Agreements
Prostrate
DCVax-Phase II
DCVax-Booster
Upcoming Events
Videos
Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |